IGM Biosciences (NASDAQ: IGMS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.610 | -1.530 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of IGM Biosciences (NASDAQ: IGMS) through any online brokerage.
Other companies in IGM Biosciences’s space includes: Avidity Biosciences (NASDAQ:RNA), Replimune Group (NASDAQ:REPL), Kiniksa Pharmaceuticals (NASDAQ:KNSA), PMV Pharma (NASDAQ:PMVP) and CTI BioPharma (NASDAQ:CTIC).
The latest price target for IGM Biosciences (NASDAQ: IGMS) was reported by Baird on Wednesday, June 1, 2022. The analyst firm set a price target for 31.00 expecting IGMS to rise to within 12 months (a possible 68.75% upside). 15 analyst firms have reported ratings in the last year.
The stock price for IGM Biosciences (NASDAQ: IGMS) is $18.37 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for IGM Biosciences.
IGM Biosciences’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for IGM Biosciences.
IGM Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.